Reviewing CTI BioPharma Corp. (CTIC)’s and Geron Corporation (NASDAQ:GERN)’s results

Both CTI BioPharma Corp. (NASDAQ:CTIC) and Geron Corporation (NASDAQ:GERN) are Biotechnology companies, competing one another. We will contrast their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CTI BioPharma Corp. 12.28M 4.48 44.51M -0.87 0.00
Geron Corporation N/A 329.60 27.15M -0.16 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of CTI BioPharma Corp. and Geron Corporation.


Table 2 shows us CTI BioPharma Corp. and Geron Corporation’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
CTI BioPharma Corp. -362.46% -77.4% -49.1%
Geron Corporation 0.00% -19.2% -18.5%

Risk and Volatility

A beta of -0.41 shows that CTI BioPharma Corp. is 141.00% less volatile than Standard & Poor’s 500. Geron Corporation’s 143.00% more volatile than Standard & Poor’s 500 which is a result of the 2.43 beta.


The Current Ratio and a Quick Ratio of CTI BioPharma Corp. are 3.6 and 3.6. Competitively, Geron Corporation has 37.8 and 37.8 for Current and Quick Ratio. Geron Corporation’s better ability to pay short and long-term obligations than CTI BioPharma Corp.

Institutional and Insider Ownership

CTI BioPharma Corp. and Geron Corporation has shares held by institutional investors as follows: 62.1% and 31.1%. Insiders held roughly 0.1% of CTI BioPharma Corp.’s shares. On the other hand, insiders held about 0.47% of Geron Corporation’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CTI BioPharma Corp. -11.9% -14.45% -23.32% -69.86% -43.94% -44.78%
Geron Corporation -12.42% -18.02% -77.62% -62.2% -29.15% -21.67%

For the past year CTI BioPharma Corp.’s stock price has bigger decline than Geron Corporation.


On 8 of the 9 factors Geron Corporation beats CTI BioPharma Corp.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.